Identification of Galeterone's mechanism of action leading to novel treatment therapies for castrate resistant prostate cancer (CRPC)

Case ID:

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (HRPC), is a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT).  The need for effective therapies for these difficult to treat cancers is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.

WSU researchers have developed novel treatments and diagnostics for cancers. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. Simultaneously developed diagnostics can measure biomarkers that are androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for CRPC and may have efficacy in other cancers, such as multiple myeloma (MM).


Patent Information:
For Information, Contact:
Ken Massey
Wayne State University
Qingping Dou
Huanjie Yang
Elisabeth Heath